Lexicon extends intellectual property portfolio with patent on gene trapping.
The 988 patent covers cells that have been genetically engineered using Lexicon's third-generation gene trapping constructs. The newly-issued patent covers the substantial majority of the more than 270,000 embryonic stem cell clones present in Lexicon's OmniBank library and identified by DNA sequence in Lexicon's OmniBank database. The patent also covers the cells of knockout mice and other model organisms containing genetic modifications that were made using the technology.
Lexicon scientists use gene knockout technology -- both gene trapping and gene targeting -- to systematically discover the physiological functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon has a pipeline of more than 40 drug discovery programs that resulted from discoveries made using these patented technologies.
Lexicon is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, cancer, immune system disorders, ophthalmic disease, and psychiatric and neurological disorders. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries.
Lexicon Genetics, Inc.
|Printer friendly Cite/link Email Feedback|
|Comment:||Lexicon extends intellectual property portfolio with patent on gene trapping.|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 2004|
|Previous Article:||Pharming acquires patent portfolio of PPL therapeutics.|
|Next Article:||Corgentech announces patent issuance for E2F transcription factor decoy technology.|